These emerging treatments, Tirzepatide , represent a significant advancement in managing obesity and potentially associated ailments . These drugs are categorized as GLP-1 hormone agonists , meaning https://nicolegheh839638.bloggadores.com/40193173/tirzepatide-a-thorough-exploration-into-incretin-agents